Peptides for Muscle Growth: What the Evidence Shows

Search for peptides for muscle growth and you will find a dozen compounds presented as interchangeable shortcuts. They are not interchangeable, and the honest summary of the category is narrower than any vendor page will tell you.

This is an educational overview of what the research shows. These are largely unapproved research chemicals, not products anyone should be taking, and nothing here is medical advice.

What does the evidence actually say?

Synptide grades evidence outcome by outcome — a compound can be well supported for one thing and unsupported for another. Graded specifically on muscle growth or lean body mass, the growth-hormone-axis compounds look like this:

Compound	Grade for muscle / body composition
MK-677	C — increase in fat-free mass
GHRP-2	E — unsupported
GHRP-6	E — unsupported
Ipamorelin	U — unknown
CJC-1295	U — unknown
Sermorelin	U — unknown
Tesamorelin	U — unknown (outside HIV lipodystrophy)

One C. Two graded E, meaning the evidence actively fails to support the claim. Four unknown.

Across the entire category, exactly one compound has graded human evidence for increasing lean mass — and it was abandoned in late-stage development because that lean mass did not translate into anything patients could feel.

Why did the one that works get abandoned?

MK-677 is the interesting case, and worth understanding before treating its C grade as a recommendation.

It is an orally active ghrelin-receptor agonist that durably raises growth hormone and IGF-1 in humans — the best-studied compound in this class by a wide margin. It does increase fat-free mass. It reached late-stage trials at Merck and was never approved, because increasing lean mass did not produce a corresponding clinical benefit.

That distinction is the whole story of this category. Fat-free mass on a DEXA scan is a surrogate endpoint. Strength, function, and outcomes are what the surrogate is supposed to predict, and here it did not.

The full MK-677 profile covers the metabolic trade-offs — insulin resistance and raised blood glucose among them — that came with it.

Do growth hormone secretagogues build muscle?

They raise growth hormone. Whether that builds muscle is a separate question, and the answer is not established.

Secretagogues increase GH pulse amplitude substantially, but leave serum GH well below the levels achieved by injected growth hormone — and the outcome data behind either approach is thin. The comparison is worked through in do secretagogues beat direct HGH.

This is why ipamorelin and CJC-1295 are graded C for raising GH and U for muscle growth. The hormonal effect is real and measurable. The downstream effect is not demonstrated.

Hexarelin illustrates the failure mode directly: a potent secretagogue that was sidelined by tachyphylaxis — the response fading with continued use — and by cortisol and prolactin release alongside the GH.

What about IGF-1 LR3 and PEG-MGF?

These skip the GH step and act further down the pathway, which sounds like it should work better.

The mechanisms are real biology. The human evidence for injecting either one is essentially absent, and they carry the risk profile of a growth factor administered without clinical supervision.

What about myostatin inhibitors?

Blocking myostatin — the brake on muscle growth — is the most mechanistically compelling idea in the category, and it has been tested properly in humans.

The results were sobering. Domagrozumab, a myostatin-pathway antibody, went through a randomized phase 2 trial in Duchenne muscular dystrophy and Pfizer subsequently terminated the programme. Muscle-mass increases in these trials have generally not delivered proportional strength or function gains — the same surrogate-versus-outcome gap that sank MK-677.

Follistatin and myostatin covers what did and did not translate.

Frequently asked questions

Do peptides actually build muscle?

No peptide in this category has demonstrated a muscle-growth benefit in humans that survived proper trials. One compound, MK-677, increases fat-free mass and is graded C for that outcome — but it failed to convert that into clinical benefit and was never approved.

Which peptide is best for muscle growth?

The question assumes a winner exists. On graded evidence, two of the commonly sold options are unsupported, four are unknown, and the one with data was abandoned in development. There is no evidence-based answer to “which is best.”

Are muscle-growth peptides legal?

Most are sold as research chemicals, not approved for human use. Legality, purity, and identity are separate problems from efficacy — see what “for research use only” actually means.

Does raising growth hormone build muscle?

Raising GH is measurable; building muscle is the claim that follows from it, and that step is not established. Compounds graded C for raising GH are graded U for muscle growth precisely because the second does not follow automatically from the first.

What actually builds muscle?

Resistance training and adequate protein, with the dose-response relationships that have been studied in humans for decades — see weekly sets and hypertrophy and protein for muscle retention. That is an unglamorous answer with vastly more evidence behind it than anything on this page.

The takeaway

The peptides marketed for muscle growth are not a spectrum from weaker to stronger. They are a category in which one compound has real lean-mass data and was abandoned for failing to deliver benefit, two are graded as unsupported, and the rest have no human evidence for the claim at all.

The mechanisms are frequently real — GH does rise, IGF-1 signalling does drive hypertrophy in models, myostatin blockade does increase muscle mass in animals. What has repeatedly failed is the translation from mechanism to a result a person would notice.

That gap is the single most important thing to understand before evaluating anything in this category, and it is why the honest grade for most of it is U.